Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Damora Therapeutics, Inc.NASDAQ: DMRA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income of -$27.78M in Q1 FY2026
Q1 FY2026 net income was -$27.78M. Trailing-twelve-month net income was -$25.43M. Over 3 fiscal years it compounded at +50.4% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$2.48M (-98.8%) for the fiscal year ending Dec 2026, a slowdown from the +878.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$27.78M-86.2% QoQ
- Last fiscal yearDec 2025
- -$209.84M+878.8% YoY
- LTMJun 2024
- -$25.43M-50.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +878.8% | -98.8% | -977.6 pp |
| 3-year CAGR | +50.4% | -74.8% | -125.3 pp |
| 5-year CAGR | -56.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (209.84M) USD
- Year-over-year change
- -878.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (209.84M) | -878.8% |
| FY2024 | 2024-12-31 | (21.44M) | +44.1% |
| FY2023 | 2023-12-31 | (38.35M) | +37.8% |
| FY2022 | 2022-12-31 | (61.62M) | -19.1% |
| FY2021 | 2021-12-31 | (51.75M) | — |
Net Income vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's LTM Jun 2024 net income of $25.43M is the smallest of the 9 companies compared; the peer median is $65.61M.
- Over three fiscal years its annual growth of +50.4% compares with a peer median of +16.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.61B | +85.1% | +55.7% | 27.7% | |
| LTM Jun 2026 | $861.1M | — | -48.4% | 20.8% | |
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $243.1M | +34.2% | +65.5% | — |
| LTM Mar 2026 | $208.87M | -4.0% | +16.2% | 1154.4% | |
| LTM Mar 2026 | $85.15M | -2121.5% | — | 256.6% | |
| LTM Mar 2026 | $67.31M | -51.6% | -15.4% | 34.3% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $63.91M | — | — | — |
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $25.43M | — | +50.4% | — |
| Peer median (excluding DMRA) | $65.61M | +15.1% | +16.2% | 77.9% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 998K |
| Change in Working Capital | (6.62M) | 11.94M | (4.37M) | (2.67M) | 18.36M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.32M) | 1.82M | (1.65M) | (1.33M) | 17.27M |
| Other Working Capital | (5.3M) | 10.12M | (2.72M) | (1.34M) | 1.09M |
| Other Non-Cash Items | 5.63M | 6.27M | 4.98M | 5.3M | 183.72M |
| Operating Cash Flow | (52.31M) | (42.93M) | (36.91M) | (18.62M) | (6.73M) |
| Capital Expenditures | (223K) | (196K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 83K | 0 | (17.37M) |
| Purchases of Investments | (84.21M) | (44.87M) | (25.94M) | 0 | 0 |
| Sales of Investments | 36.38M | 57.45M | 48.18M | 11.65M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (48.05M) | 12.38M | 22.33M | 11.65M | (17.37M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 507K | 2.88M | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 33K |
| Financing Cash Flow | 0 | 507K | 2.88M | 0 | 266.84M |
| Effect of Forex Changes | (663K) | 264K | 384K | (317K) | 705K |
| Net Change in Cash | (101.02M) | (29.78M) | (11.32M) | (7.29M) | 243.45M |
| Free Cash Flow | (52.53M) | (43.13M) | (36.91M) | (18.62M) | (6.73M) |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.